News & Updates
Filter by Specialty:
Benralizumab helps maintain severe asthma control with reduced ICS doses
Treatment with benralizumab allows tapering of inhaled corticosteroid (ICS) doses for patients with severe eosinophilic asthma, without compromising disease control and increasing exacerbations, as shown in the results of the phase IV SHAMAL study.
Benralizumab helps maintain severe asthma control with reduced ICS doses
22 Sep 2023
Cefoperazone-sulbactam superior to piperacillin-tazobactam for severe CAP
Treatment with cefoperazone-sulbactam demonstrates similar efficacy to that of piperacillin-tazobactam in adult patients with severe community-acquired pneumonia (SCAP), according to a study. However, after adjusting for disease severity, cefoperazone-sulbactam appears superior to piperacillin-tazobactam.
Cefoperazone-sulbactam superior to piperacillin-tazobactam for severe CAP
21 Sep 2023
Zuranolone improves symptoms in adults with major depressive disorder
Treatment with zuranolone 50 mg/day in adults with major depressive disorder (MDD) results in greater improvements in depressive symptoms at day 15, demonstrating a rapid time to effect (day 3), and is generally well tolerated, with no new safety concerns compared with lower dosages, reports a study.
Zuranolone improves symptoms in adults with major depressive disorder
21 Sep 2023
Budesonide falls short of improving hyposmia related to COVID-19
Local intranasal treatment with budesonide does not appear to be effective for persistent hyposmia in patients with nonsevere COVID-19, according to a study.
Budesonide falls short of improving hyposmia related to COVID-19
21 Sep 2023
Zuranolone safe, effective for postpartum depression
Use of zuranolone significantly improves depressive symptoms, with no serious side effects, in women with severe postpartum depression (PPD), a common perinatal complication with adverse maternal and infant outcomes, results of a phase III trial have shown.